Sjögren's syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: A case

Abstract

The objective of this study was to investigate the clinical characteristics and prognosis of Sjögren’s syndrome-onset systemic lupus erythematosus (SS/SLE) patients. Medical charts of 41 consecutive SS/SLE inpatients admitted to Peking Union Medical College Hospital (PUMCH) from February 1998 to February 2008 were systematically reviewed, including demographic data, clinical features, laboratory findings, treatment as well as outcomes. Two hundred and fourteen cases were randomly selected as controls from 2331 SLE-only inpatients treated in PUMCH at the same time period. There were significant differences between SS/SLE and SLE-only patients in the following manifestations (p < 0.05): (1) sex ratio (F/M) (41/0 versus 184/30), age (42.8 ± 41.0 years versus 31.8 ± 31.0 years), disease duration (113.8 ± 84.0 months versus 44.9 ± 18.0 months); (2) clinical features, xerostomia (85.4% versus 6.1%), xerophthalmia (75.6% versus 2.3%), renal tubular acidosis (21.9% versus 0%), interstitial lung disease (12.2% versus 2.8%), facial rash (9.8% versus 46.3%), nephrotic syndrome (7.3% versus 31.3%), central nervous system involvement (4.9% versus 19.6%); (3) laboratory findings, ESR (64.6±75.0mm/h versus 46.5±34.0mm/h), C4 (14.8 ± 12.2 g/dl versus 12.0 ± 10.9 g/dl), IgG elevation (56.4% versus 29.9%) and IgA elevation (38.5% versus 20.4%), RF, anti-SSA and anti-SSB positive rates (70.8% versus 20.3%, 82.9% versus 43.4% and 39.0% versus 7.9%); (4) SLEDAI score (8.0 ± 8.0 versus 10.2 ± 10.0), glucocorticoid treatment (methylprednisolone bolus/1—2 mg kg^-1 day^-1 prednisone/<1 mg kg^-1 day^-1 prednisone) (8/26/7 versus 91/102/21), and importantly, rate of death and/or severe irreversible organ failure (2.4% versus 14.9%). SS/SLE patients were followed up for 33.0 ± 34.0 months, 40 cases remained stable at a low dose of corticosteroid. In conclusion, different from SLE-only patients, SS/SLE patients have distinctive clinical manifestations and benign prognosis that require less vigorous treatment with glucocorticoids and/or immunosuppressants. Lupus (2010) 19, 197—200.

Keywords

prognosis Sjögren’s syndrome systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Fox RI Sjogren’s syndrome. Lancet 2005; 366: 321-331.

Kassan SS , Moutsopoulos HM Clinical manifestations and early diagnosis of Sjogren’s syndrome. Arch Intern Med 2004; 164: 1275-1284.

Ramos-Casals M. , Tzioufas AG , Font J. Primary Sjogren’s syndrome: New clinical and therapeutic concepts. Ann Rheum Dis 2005 ; 64: 347-354.

Menelaos NM , Chryssoula G. , Elias Z. , et al. Sjogren’s syndrome associated with systemic lupus erythematosus: Clinical and analytic profiles and comparison with primary Sjogren’s syndrome. Arthritis Rheum 2004; 50: 882-891.

Gilboe IM , Kvien TK , Uhlig T. , et al. Sicca symptoms and secondary Sjogren’s syndrome in systemic lupus erythematosus: Comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis 2001 ; 60: 1103-1109.

Nossent JC , Swaak AJ Systemic lupus erythematosus VII: Frequency and impact of secondary Sjogren’s syndrome. Lupus 1998; 7: 231-234.

Zufferey P. , Meyer OC , Bourgeois P. , et al. Primary systemic Sjogren’s syndrome (SS) preceding systemic lupus erythematosus: A retrospective study of 4 cases in a cohort of 55 SS patients. Lupus 1995; 4: 23-27.

Sjögren's syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: A case—control study

Abstract

Keywords

Get full access to this article

References